Related by context. All words. (Click for frequent words.) 73 ixabepilone 72 ASA# 72 pertuzumab 72 axitinib 71 Herceptin trastuzumab 70 IMC A# 70 AP# [003] 69 IMGN# 69 HER2 positive metastatic breast 69 ipilimumab 69 trastuzumab DM1 69 BAY #-# 69 Avastin 69 tanespimycin 68 aflibercept 68 Erbitux 68 Avastin bevacizumab 68 panitumumab 68 enzastaurin 68 neratinib 68 tesmilifene 68 Targretin 68 Vectibix 68 Amrubicin 67 BRAF inhibitor 67 mapatumumab 67 Nexavar 67 carfilzomib 67 bevacizumab Avastin 67 Erbitux cetuximab 67 VEGF Trap 67 sapacitabine 66 denosumab 66 temsirolimus 66 afatinib 66 Telcyta 66 ganetespib 66 PXD# 66 Imprime PGG 66 phase IIb clinical 66 PLX# 66 perifosine 66 Xcytrin 66 Telaprevir 66 vandetanib 66 glufosfamide 66 Tarceva 66 Pertuzumab 66 GVAX 66 docetaxel 66 pomalidomide 65 Zolinza 65 Xyotax 65 Folotyn 65 lapatinib 65 Jevtana 65 lintuzumab 65 Ceflatonin 65 Hycamtin 65 CoFactor 65 dacetuzumab 65 TELCYTA 65 Actemra 65 satraplatin 65 iniparib 65 Carfilzomib 65 trastuzumab 65 Tykerb 65 Nexavar ® 65 Advexin 65 FTY# 65 HuMax CD# 65 obatoclax 65 Taxotere ® 65 Genasense 65 Taxotere 65 elotuzumab 65 docetaxel Taxotere R 65 Treanda 65 standard chemotherapy regimen 65 sorafenib Nexavar 65 Velcade bortezomib 65 metastatic renal cell carcinoma 64 CR# vcMMAE 64 cetuximab Erbitux 64 YONDELIS 64 OncoVEX GM CSF 64 carboplatin paclitaxel 64 HuMax CD4 64 sunitinib 64 PTK ZK 64 Aflibercept 64 dasatinib 64 trabectedin 64 alvespimycin 64 abiraterone 64 platinum refractory 64 sunitinib malate 64 HuMax EGFr 64 HRPC 64 cediranib 64 Tarceva TM 64 huC# DM4 64 Proxinium TM 64 seliciclib 64 topotecan 64 docetaxel chemotherapy 64 PROSTVAC TM 64 vemurafenib 64 Panitumumab 64 taxane 64 pazopanib 64 mTOR inhibitor 64 Revlimid 64 pralatrexate 63 figitumumab 63 cetuximab 63 Trastuzumab 63 IMA# 63 INCB# [001] 63 Bortezomib 63 Abraxane 63 Revlimid lenalidomide 63 JAK inhibitor 63 gemcitabine 63 Pixantrone 63 Satraplatin 63 valopicitabine 63 temozolomide 63 talactoferrin 63 Perifosine 63 Telavancin 63 zalutumumab 63 Sym# 63 Phase Ib study 63 Marqibo 63 Ixempra 63 Rituxan 63 HGS ETR1 63 nilotinib 63 Velcade 63 mertansine 63 oral ridaforolimus 63 PSMA ADC 63 ADVEXIN 63 XmAb# 63 Nexavar sorafenib 63 MGCD# [001] 63 RAD# [003] 63 phase IIb 63 Campath 63 IMC #B 63 Doxil 63 OncoVEX 63 Sorafenib 63 sorafenib 63 Zactima 63 Tarceva erlotinib 63 Abiraterone acetate 63 vorinostat 63 Phase Ib 63 Azedra 63 HGS# 63 thymalfasin 63 Phase Ib II 63 BRIM2 63 Aplidin 63 Vandetanib 63 tremelimumab 63 picoplatin 63 YERVOY 63 adecatumumab 62 metastatic colorectal cancer 62 belinostat 62 Yervoy 62 HGS ETR2 62 Asentar 62 CD# antibody [001] 62 XL# [003] 62 relapsed refractory multiple myeloma 62 Erlotinib 62 teriflunomide 62 Vidaza 62 Sutent 62 ocrelizumab 62 Herceptin 62 olaparib 62 Bevacizumab 62 CYC# 62 nab paclitaxel 62 GALNS 62 registrational 62 Lapatinib 62 Pfizer Sutent 62 clofarabine 62 amrubicin 62 Allovectin 7 ® 62 SinuNase 62 Fludara 62 radiation sensitizer 62 Denosumab 62 Omnitarg 62 Neuvenge 62 Phase 2b trial 62 MDV# 62 investigational humanized monoclonal antibody 62 ZYBRESTAT 62 Xinlay 62 LY# [003] 62 REOLYSIN ® 62 palifosfamide 62 cutaneous T cell 62 resistant ovarian cancer 62 ERBITUX 62 Dendreon Provenge 62 gemcitabine chemotherapy 62 angiogenesis inhibitor 62 Reolysin 62 metastatic hormone refractory 62 trastuzumab Herceptin 62 ZACTIMA 62 registrational trial 62 Phase 2a trial 62 Yondelis 62 SAR# [004] 62 MAGE A3 ASCI 62 Dacogen 62 Celgene Revlimid 62 bortezomib 62 talabostat 62 PEG SN# 62 CA4P 62 dalbavancin 62 investigational compound 62 Pazopanib 62 rNAPc2 62 sorafenib tablets 62 regorafenib 62 RG# [001] 62 voreloxin 62 proteasome inhibitor 62 L BLP# 62 brentuximab vedotin 62 Ipilimumab 62 Bezielle 62 trastuzumab DM1 T DM1 62 Ixabepilone 62 Gemcitabine 62 Gemzar 61 Taxotere docetaxel 61 Ocrelizumab 61 Clolar 61 daclizumab 61 PEG Interferon lambda 61 Sprycel 61 AQ4N 61 Orathecin 61 TREANDA 61 docetaxel Taxotere 61 ponatinib 61 Phase 1b 61 infusional 5-FU/LV 61 Docetaxel 61 GV# [001] 61 Zevalin 61 deforolimus 61 FOLOTYN 61 gefitinib 61 rituximab 61 Vitaxin 61 Golimumab 61 Phase III 61 Mipomersen 61 KRN# 61 tesetaxel 61 eniluracil 61 dose cohorts 61 trastuzumab emtansine 61 Antegren 61 telaprevir 61 Viramidine 61 bevacizumab 61 MetMAb 61 Immunogen 61 TRISENOX 61 anticancer therapy 61 Dacogen injection 61 relapsed ovarian cancer 61 atrasentan 61 epothilone 61 celgosivir 61 dirucotide 61 integrase inhibitor 61 AVADO 61 erlotinib Tarceva 61 Canvaxin 61 biologic therapy 61 tocilizumab 61 bazedoxifene 61 vascular disrupting agent 61 SUTENT 61 zanolimumab 61 phase IIa clinical 61 GRN#L 61 AEG# 61 ThermoDox 61 decitabine 61 IIa trial 61 BiovaxID 61 romidepsin 61 TYKERB 61 LymphoStat B 61 low dose cytarabine 61 Voreloxin 61 eltrombopag 61 Temsirolimus 61 ZK EPO 61 pegylated liposomal doxorubicin 61 NKTR 61 Dasatinib 61 phase IIb trial 61 crizotinib PF # 61 farletuzumab 61 ZEVALIN 61 ANYARA 61 capecitabine Xeloda 61 kinase inhibitors 61 RSR# 61 OXi# 60 Cimzia 60 lorvotuzumab mertansine 60 Axitinib 60 SCH # 60 Azixa 60 Reverset 60 EndoTAG TM -1 60 ZOLINZA 60 docetaxel Taxotere ® 60 bosutinib 60 Nanobody 60 relapsed multiple myeloma 60 Glufosfamide 60 Panzem R NCD 60 MyVax 60 TNFerade 60 motesanib 60 hormone refractory prostate cancer 60 HuLuc# 60 elacytarabine 60 Torisel 60 trastuzumab emtansine T DM1 60 Dapagliflozin 60 ofatumumab 60 IL# PE#QQR 60 bendamustine 60 Pralatrexate 60 oxaliplatin 60 sorafenib Nexavar ® 60 midstage studies 60 kinase inhibitor 60 EOquin 60 PrevOnco 60 Taxotere R 60 Xgeva 60 TORISEL 60 Allovectin 7 60 PDE4 inhibitor 60 AZD# 60 SUCCEED trial 60 Mylotarg 60 sipuleucel T 60 bortezomib Velcade 60 anticancer therapies 60 humanized monoclonal antibody 60 Vilazodone 60 Irinotecan 60 EFAPROXYN 60 Vectibix panitumumab 60 FOLFIRI 60 monotherapy 60 Fablyn 60 CBLC# 60 ToGA 60 Roche Chugai s 60 gastrointestinal stromal tumors 60 tubulin inhibitor 60 Alocrest 60 erlotinib 60 ISENTRESS 60 Novartis Zometa 60 HER2 positive breast cancer 60 Rituxan rituximab 60 cilengitide 60 elesclomol 60 vismodegib 60 Phase 2b clinical 60 Panzem 60 Cloretazine R VNP#M 60 randomized Phase 60 anti EGFR antibody 60 CCX# 60 Alpharadin 60 pixantrone 60 REVLIMID 60 lapatinib Tykerb 60 tyrosine kinase inhibitors 60 entinostat 60 Phase III trials 60 PARP inhibitor 60 ImClone Erbitux 60 Tanespimycin 60 HER2 positive 60 cabozantinib 60 bevacizumab Avastin ® 60 Trastuzumab DM1 60 tyrosine kinase inhibitor 60 AEGR 60 assessing T DM1 60 Femara 60 Tyrima 60 Abiraterone 60 Phase #/#a trial 60 Novartis Gleevec 60 metastatic castration resistant 60 OPAXIO 60 fingolimod 60 cabazitaxel 60 PARP inhibitors 60 Laquinimod 60 paclitaxel Taxol 60 ADXS# 60 relapsed GBM 60 ATL# [001] 60 heavily pretreated 60 FOLFOX 60 INCB# [002] 60 DAVANAT 60 XELOX 60 Oncophage 60 Urocidin 60 abiraterone acetate 59 dose escalation 59 MEK inhibitors 59 investigational monoclonal antibody 59 mRCC 59 lumiliximab 59 LUX Lung 59 molecularly targeted 59 orally bioavailable 59 gemcitabine carboplatin 59 Maraviroc 59 Merck KGaA Erbitux 59 MyVax R 59 MEK inhibitor 59 dose escalation Phase 59 proteasome inhibitors 59 capecitabine Xeloda R 59 Xelox 59 MLN# 59 Arzerra 59 pivotal Phase III 59 monoclonal antibody 59 multi kinase inhibitor 59 PROVENGE 59 Phase Ib clinical 59 receptor tyrosine kinase inhibitor 59 ProLindac 59 recurrent ovarian cancer 59 NVA# 59 Junovan 59 Onrigin 59 cetuximab Erbitux ® 59 carboplatin 59 Ambrisentan 59 OvaRex ® MAb 59 Genentech Herceptin 59 anidulafungin 59 darapladib 59 panobinostat 59 PF # [001] 59 TroVax 59 ACTEMRA 59 anti TNF 59 galiximab 59 erlotinib Tarceva ® 59 pan HDAC inhibitor 59 castration resistant prostate cancer 59 GLPG# 59 adjuvant colon cancer 59 phase Ib 59 anticancer agents 59 lymphoma CTCL 59 iclaprim 59 Pemetrexed 59 Phase III clinical 59 Exelixis XL# 59 Archexin 59 LBH# 59 Fusilev 59 indolent NHL 59 evaluating tivozanib 59 follicular NHL 59 panitumumab Vectibix 59 Tarvacin 59 fluoropyrimidine 59 EOquin TM 59 drug conjugate 59 OMAPRO 59 EndoTAG 59 custirsen 59 ASONEP 59 metaglidasen 59 methylnaltrexone 59 Cloretazine ® 59 lasofoxifene 59 Cloretazine 59 Zalbin 59 RGB # 59 tamibarotene 59 anti leukemic 59 cladribine 59 metastatic HRPC 59 cytarabine 59 maraviroc 59 SCCHN 59 IAP inhibitors 59 immunotherapeutic agent 59 dexpramipexole 59 metastatic melanoma 59 azacitidine 59 Prostate AdenoCarcinoma Treatment 59 NXL# 59 bortezomib Velcade R 59 NP2 Enkephalin 59 chemotherapeutic regimen 59 refractory multiple myeloma 59 Genentech Roche 59 dacarbazine 59 ustekinumab 59 mipomersen 59 trastuzumab Herceptin R 59 Vicinium TM 59 blinatumomab 59 dose escalation trial 59 refractory AML 59 elagolix 59 metastatic kidney 59 LAF# 59 ELND# 59 metastatic castrate resistant 59 forodesine 59 Darusentan 59 BZL# 59 Ofatumumab 59 Aurora kinase inhibitor 59 metastatic CRC 59 alogliptin 59 anti TNF alpha 59 Theratope 59 anti angiogenic therapy 59 imatinib 59 Genasense ® 59 MGCD# [002] 59 Alemtuzumab 59 Tamibarotene 59 Blinatumomab 59 #D#C# 59 bapineuzumab 59 JAK inhibitors 59 tezampanel 59 TMC# [001] 59 ridaforolimus 59 Provenge 59 vicriviroc 59 ELACYT 59 Traficet EN 59 NSCLC 58 antitumor activity 58 IRX 2 58 paclitaxel carboplatin 58 GSK# [001] 58 FOLOTYN ® 58 randomized Phase III 58 CYT# 58 Sapacitabine 58 Phase IIb trial 58 TroVax ® 58 Platinol 58 pemetrexed 58 apremilast 58 arzoxifene 58 EndoTAGTM 1 58 relapsing remitting multiple sclerosis 58 Taxol paclitaxel 58 Fludara ® 58 rindopepimut 58 Tesetaxel 58 BrachySil 58 ONGLYZA ™ 58 5 fluorouracil leucovorin 58 cisplatin 58 Phase III clinical trials 58 TELINTRA 58 Afatinib 58 Corlux 58 HCV protease inhibitor 58 Apixaban 58 goserelin 58 imatinib Gleevec 58 Carboplatin 58 Xanafide 58 INC# 58 otelixizumab 58 Virulizin ® 58 Atiprimod 58 oral antiviral 58 Rituximab 58 gefitinib Iressa 58 PROCHYMAL 58 oral Xeloda 58 Folfox 58 Boceprevir 58 Clofarabine 58 Yondelis ® 58 liposomal formulation 58 Campath alemtuzumab 58 huN# DM1 58 Synavive 58 Taxotere chemotherapy 58 Alimta 58 PLK1 SNALP 58 Arimoclomol 58 heavily pretreated patients 58 TEMODAL 58 Rexin G 58 chemotherapeutic agent 58 Tavocept 58 imetelstat 58 Pirfenidone 58 Santhera 58 HspE7 58 Arcalyst 58 IRESSA 58 refractory APL 58 Zybrestat 58 cetuximab Erbitux R 58 Hsp# inhibition 58 Elotuzumab 58 CD3 monoclonal antibody 58 Gemzar ® 58 Sutent sunitinib 58 seliciclib CYC# 58 bicifadine 58 MGd 58 selective androgen receptor modulator 58 PRX # 58 vascular disrupting agents 58 RDEA# 58 histone deacetylase HDAC inhibitor 58 Cladribine 58 immunomodulator 58 letrozole 58 recurrent NSCLC 58 Ilaris 58 Onconase 58 vinorelbine 58 TBC# 58 Debio 58 VIDAZA 58 Epratuzumab 58 Arranon 58 liposomal doxorubicin 58 Phenoptin 58 EGFR inhibitors 58 ThermoDox R 58 pegylated interferon alpha 58 paclitaxel Taxol ® 58 Onco TCS 58 Pegintron 58 Phase IIa trial 58 TACI Ig 58 Phase 2b study 58 MORAb 58 ruxolitinib 58 Zarnestra 58 humanised monoclonal antibody 58 Amigal 58 radioimmunotherapy 58 APF# 58 trabedersen 58 luteinizing hormone releasing 58 EGFR TKI 58 midstage trials 58 adjuvant therapy 58 hA# 58 cancer immunotherapies 58 vinflunine 58 pradefovir 58 dasatinib Sprycel 58 epothilones 58 Gleevec imatinib mesylate 58 ZD# [001] 58 XGEVA 58 Bicifadine 58 placebo controlled Phase 58 chemotherapeutic drug 58 Orencia 58 HER2 + 58 metastatic RCC 58 IgG1 monoclonal antibody 58 recurrent GBM 58 Dalbavancin 58 HCD# [002] 58 BRIM3 57 OMP #M# 57 Onyx Pharma 57 Vicriviroc 57 reslizumab 57 biologic therapies 57 HER2 antibody 57 ISIS # 57 atacicept 57 Eribulin 57 CIMZIA TM 57 therapeutic antibody 57 milatuzumab 57 MOZOBIL 57 bone metastasis 57 lupus nephritis 57 IMPACT IMmunotherapy 57 protein kinase inhibitor 57 EGFr 57 Phase IIb clinical trials 57 TG# [001] 57 brentuximab vedotin SGN 57 PRT# 57 Crizotinib 57 BMS # 57 Troxatyl 57 Civacir 57 Litx 57 AMN# [001] 57 Gefitinib 57 PSN# [002] 57 Gleevec 57 Krystexxa 57 aromatase inhibitor 57 phase 2a 57 Nuvion 57 Diamyd ® 57 anticancer agent 57 bone metastases 57 Phase #b/#a clinical 57 Seliciclib 57 Tykerb lapatinib 57 Talabostat 57 AVASTIN 57 PI3K/Akt pathway inhibitor 57 cytokine refractory 57 Promacta 57 SERMs 57 metastatic colon cancer 57 HDAC inhibitor 57 mTOR inhibitors 57 metastatic colorectal 57 MAbs 57 Daclizumab 57 Phase IIIb clinical 57 XYOTAX TM 57 antibody MAb 57 sorafenib Nexavar R 57 Gleevec imatinib 57 standard chemotherapy regimens 57 pegloticase 57 Lenocta 57 MAP# 57 solid tumors 57 orBec 57 systemic ALCL 57 BRAF inhibitors 57 anastrozole 57 Hsp# inhibitor 57 plus dexamethasone 57 relapsed SCLC 57 investigational pan BCR 57 CRx 57 Atrasentan 57 pivotal Phase 57 Phase 1b trial 57 ILLUMINATE 57 KNS # 57 Afinitor 57 Provenge prostate cancer 57 alvimopan 57 Randomized Phase 57 hematological cancers 57 Syncria 57 advanced NSCLC 57 relapsed refractory 57 XYOTAX 57 Romidepsin 57 thalidomide Thalomid 57 Cubicin 57 DMARD 57 KRAS status 57 Panzem NCD 57 relapsing multiple sclerosis 57 INTELENCE 57 rituximab Rituxan 57 Pivotal Phase III 57 Phase 2b 57 gemcitabine Gemzar 57 baminercept 57 Affinitak 57 TOCOSOL Paclitaxel 57 leucovorin 57 Cisplatin 57 abatacept 57 omacetaxine 57 mCRC 57 ambrisentan 57 Annamycin 57 TASKi2 57 evaluating T DM1 57 gemcitabine Gemzar ® 57 metastatic renal cell 57 tasocitinib 57 PREOS 57 FOLFOX4 57 nimotuzumab 57 mycophenolate mofetil 57 ACZ# 57 ceftaroline 57 Phase IIb 57 TLK# 57 BCX# 57 Roche Avastin 57 diabetic neuropathic pain 57 ozarelix 57 generation antisense 57 sBLA 57 Telatinib 57 cangrelor 57 Sanofi Aventis Taxotere 57 BiTE antibody 57 Elesclomol 57 Phase IIb trials 57 Pimavanserin 57 MNTX 57 Genentech Rituxan 57 NEUVENGE 57 dasatinib Sprycel ® 57 MabThera 57 ELOXATIN 57 interferon gamma 1b 57 HER2 57 ImmunoGen 57 taxanes 57 phase IIa 57 imatinib Gleevec ® 57 Elvitegravir 57 oral cladribine 57 Cetuximab 57 Trexima 57 Aptivus ® 57 Neulasta ® 57 solanezumab 57 viral kinetic 57 ofatumumab HuMax CD# 57 CDP# 57 Elagolix 57 lesinurad 57 Phase #b/#a 57 evaluating satraplatin 57 Removab 57 eribulin mesylate 57 ARRY 57 boceprevir 57 ongoing Phase 1b 57 brostallicin 57 adalimumab Humira 57 Tasigna nilotinib 57 Guanilib 57 GW# [003] 57 Phase 1b clinical 57 Lacosamide 57 ularitide 57 LY# [002] 57 oral prodrug 57 PEG PAL 56 Tracleer 56 Exemestane 56 Xeloda 56 LUMINATE 56 tipranavir 56 VELCADE 56 cancer immunotherapy 56 BLA submission 56 metastatic sarcoma 56 Tocosol Paclitaxel 56 QVA# 56 TRC# 56 Aurora kinase 56 refractory Hodgkin lymphoma 56 elvitegravir 56 APTIVUS 56 Rebif ® 56 vidofludimus 56 pegylated interferon alfa 2b 56 plus gemcitabine 56 Genentech Roche Chugai 56 Serdaxin 56 SNT MC# 56 Mozobil 56 PegIntron 56 Brentuximab Vedotin SGN 56 Virulizin 56 PROSTVAC ® 56 GRNVAC1 56 BENLYSTA 56 LEP ETU 56 surrogate endpoint 56 viral kinetics 56 Fodosine 56 Actilon 56 novel anticancer 56 Votrient 56 taspoglutide 56 non squamous NSCLC 56 fosbretabulin 56 Zadaxin 56 investigational protease inhibitor 56 BCIRG 56 capecitabine 56 Cytoxan 56 ThermoDox ® 56 protease inhibitor 56 paclitaxel 56 polymerase inhibitor 56 ProSavin 56 Phase Ib clinical trials 56 PEP# [003] 56 unique alkylating agent 56 DOXIL 56 Doxorubicin 56 nonsmall cell lung cancer 56 Restanza 56 neoadjuvant 56 Lu AA# 56 Doxil ® 56 cytotoxic chemotherapy 56 phenoxodiol 56 QAB# 56 MyVax personalized immunotherapy 56 anticancer compound 56 bortezomib Velcade ® 56 chronic lymphocytic leukemia CLL 56 Allovectin 7 R 56 vilazodone 56 TG# [003] 56 Zenvia 56 BLP# Liposome Vaccine 56 Ustekinumab 56 BR.# 56 Ophena TM 56 Phase 2a 56 Avastin Tarceva 56 IMiDs 56 Neuradiab 56 anti angiogenesis 56 ENDEAVOR IV 56 velaglucerase alfa 56 Acapodene 56 Chemophase 56 L MTP PE 56 anthracyclines 56 alemtuzumab 56 tigecycline 56 metastatic breast cancer 56 CEQ# 56 M Vax 56 midstage study 56 linaclotide 56 Lilly Gemzar 56 autologous cellular immunotherapy 56 LHRH antagonist 56 AVE# 56 oral deforolimus 56 Enzastaurin 56 Prochymal 56 tivozanib 56 Gleevec Glivec 56 Phase III pivotal 56 Tolamba 56 dutasteride 56 Ozarelix 56 Bydureon 56 aflibercept VEGF Trap 56 Pivotal Phase